What's breaking now, across thousands of outlets.
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
[SINGAPORE] The following companies saw new developments that may affect trading of their securities on Friday (Sep 25):
The ringgit is expected to trade between RM4.08 and RM4.10 against the US dollar today, says an analyst.
The ringgit is expected to trade between RM4.08 and RM4.10 against the US dollar today, says an analyst.
Goldman Sachs Chief Regional Equity Strategist for Asia Pacific Timothy Moe explains why AI-related stocks remain good investments despite rising rates on government debt.
Revolut is moving ahead with the completion of its acquisition of Argentine bank Banco Cetelem Argentina S.A. after receiving approval from the Central Bank of Argentina, the company said in a…
The stock is roughly 1 per cent gain away from joining an elite group of companies worth at least S$2.5 trillion.
